

INTEGRATED BIOPHARMA INC  
Form 8-K  
July 28, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549  
FORM 8-K**

**CURRENT REPORT Pursuant  
to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **July 25, 2008**

**Integrated BioPharma, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**000-28876**

(Commission File Number)

**22-2407475**

(IRS Employer Identification No.)

**225 Long Avenue**

**Hillside, New Jersey**

(Address of Principal Executive Offices)

**07205**

(Zip Code)

**(973) 926-0816**

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Item 8.01 Other Items**

Integrated BioPharma, Inc. (the “Company”) announced on July 25, 2008 that it has established a record date and a distribution date with respect to the spin-off of the Company’s interest in iBioPharma, Inc. (formerly inB:Biotechnologies, Inc.) *pro rata* to all of the Company’s public stockholders.

A copy of the press release issued by the Company is attached as Exhibit 99.1 hereto.

**Item 9.01 Financial Reports and Exhibits.**

(d) Exhibits.

***Exhibit No. Description***

99.1 Press Release dated July 25, 2008



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

**INTEGRATED BIOPHARMA, Inc.**

Date: July 28, 2008

By: /s/ Dina L. Masi

Name: Dina L. Masi

Title: Chief Financial Officer